Ny behandling af kronisk hepatitis B

Ellen Sloth Andersen; Nina M Weis; Nina M Weis

Ny behandling af kronisk hepatitis B

Ellen Sloth Andersen, Nina M Weis, Nina M Weis

Institut for Klinisk Medicin

1 Citationer (Scopus)

Abstract

Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently.
Udgivelsesdato: 2008-Nov-24

Bidragets oversatte titel	New treatment of chronic hepatitis B
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	170
Udgave nummer	48
Sider (fra-til)	3937-9
Antal sider	2
ISSN	0041-5782
Status	Udgivet - 2008

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{aba1ea8b1f9143a58ae6be092c376f84,

title = "Ny behandling af kronisk hepatitis B",

abstract = "Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24",

author = "Andersen, {Ellen Sloth} and Weis, {Nina M} and Weis, {Nina M}",

year = "2008",

language = "Dansk",

volume = "170",

pages = "3937--9",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "48",

}

TY - JOUR

T1 - Ny behandling af kronisk hepatitis B

AU - Andersen, Ellen Sloth

AU - Weis, Nina M

PY - 2008

Y1 - 2008

N2 - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24

AB - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 3937

EP - 3939

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 48

ER -